|Articles|October 1, 2014
Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
New Combination Treatment Approach Studied in Pancreatic Cancer
3
U.S. Soccer Legend Kasey Keller Reveals Lymphoma Journey
4
Why Is Lung Health Key to Survivorship After Cancer Treatment?
5